R&D News | pharmaphorum

News

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

News

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

News

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.